[go: up one dir, main page]

MXPA02012682A - Metodo para administrar bisfosfonatos. - Google Patents

Metodo para administrar bisfosfonatos.

Info

Publication number
MXPA02012682A
MXPA02012682A MXPA02012682A MXPA02012682A MXPA02012682A MX PA02012682 A MXPA02012682 A MX PA02012682A MX PA02012682 A MXPA02012682 A MX PA02012682A MX PA02012682 A MXPA02012682 A MX PA02012682A MX PA02012682 A MXPA02012682 A MX PA02012682A
Authority
MX
Mexico
Prior art keywords
bisphosphonates
osteoporosis
potent
months
periods
Prior art date
Application number
MXPA02012682A
Other languages
English (en)
Inventor
Zebulun D Horowitz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26952565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA02012682(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA02012682A publication Critical patent/MXPA02012682A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los bisfosfonatos, en particular los N- bisfosfonatos mas potentes, tales como acido zolendronico y sus derivados, se pueden utilizar con resultados satisfactorios para la inhibicion prolongada de la resorcion osea en condiciones de cambio oseo anormalmente incrementado, por ejemplo osteoporosis, mediante la administracion intermitente, en donde los periodos entre las administraciones de bisfosfonato son mas largos de lo que anteriormente se consideraba apropiado, por ejemplo un intervalo de dosificacion de cuando menos aproximadamente meses, o con menos frecuencia.
MXPA02012682A 2000-06-20 2001-06-18 Metodo para administrar bisfosfonatos. MXPA02012682A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59713500A 2000-06-20 2000-06-20
US26768901P 2001-02-09 2001-02-09
PCT/EP2001/006850 WO2001097788A2 (en) 2000-06-20 2001-06-18 Method of administering bisphosphonates

Publications (1)

Publication Number Publication Date
MXPA02012682A true MXPA02012682A (es) 2003-04-25

Family

ID=26952565

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012682A MXPA02012682A (es) 2000-06-20 2001-06-18 Metodo para administrar bisfosfonatos.

Country Status (24)

Country Link
US (1) US8052987B2 (es)
EP (1) EP1296689B3 (es)
JP (2) JP4722375B2 (es)
KR (1) KR100864743B1 (es)
CN (1) CN1272013C (es)
AT (1) ATE304856T1 (es)
AU (2) AU7410901A (es)
BR (1) BR0111806A (es)
CA (1) CA2410201C (es)
CY (2) CY1113740T1 (es)
CZ (1) CZ301972B6 (es)
DE (1) DE60113537T3 (es)
DK (1) DK1296689T3 (es)
ES (2) ES2394211T3 (es)
HU (1) HU228400B1 (es)
IL (2) IL153229A0 (es)
MX (1) MXPA02012682A (es)
NO (1) NO330459B1 (es)
NZ (1) NZ523086A (es)
PL (1) PL203087B1 (es)
PT (1) PT1591122E (es)
SK (1) SK287278B6 (es)
TW (1) TWI289451B (es)
WO (1) WO2001097788A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
HU228400B1 (en) 2000-06-20 2013-03-28 Novartis Ag The use of bisphosphonates for treatment of osteoporosis
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
JP2004526747A (ja) * 2001-04-03 2004-09-02 ザ ロイヤル アレクサンドラ ホスピタル フォー チルドレン 骨移植で使用される医薬
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds
DE60317061T2 (de) 2002-05-10 2008-07-24 F. Hoffmann-La Roche Ag Ibandronsäure zur behandlung und vorbeugung von osteoporose
AU2003270196A1 (en) * 2002-09-16 2004-04-30 Kenneth W. Lyles Method for preventing or reducing secondary fractures after hip fracture
EP1553958A1 (en) * 2002-10-15 2005-07-20 Novartis AG Method of administering bisphosphonates
AU2003250218B2 (en) 2002-12-20 2006-10-26 F. Hoffmann-La Roche Ag High dose Ibandronate formulation
WO2005072746A1 (ja) * 2004-01-30 2005-08-11 Astellas Pharma Inc. P2x受容体阻害剤
EP1930011B1 (en) * 2004-08-23 2011-08-17 Teva Pharmaceutical Industries Ltd Crystalline form of ibandronate sodium
BRPI0518874A2 (pt) 2004-12-09 2008-12-16 Merck & Co Inc composto, composiÇço farmacÊutica, e, usos de um composto, e de uma composiÇço
US7709508B2 (en) 2004-12-09 2010-05-04 Merck Sharp & Dohme Estrogen receptor modulators
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
WO2007124274A1 (en) * 2006-04-21 2007-11-01 The Uab Research Foundation Treating neoplasms
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
US20100068211A1 (en) * 2008-02-08 2010-03-18 Bateman Ted A Use of antiresorptive compounds to prevent ionizing radiation-induced activation of osteoclasts and resulting bone loss
JP5671451B2 (ja) * 2008-05-07 2015-02-18 メリオン・リサーチ・Ｉｉｉ・リミテッド ＧｎＲＨ関連化合物の組成物および調製プロセス
WO2010099255A1 (en) * 2009-02-25 2010-09-02 Merrion Research Iii Limited Composition and drug delivery of bisphosphonates
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
AU2010278860B2 (en) 2009-07-31 2016-05-26 Thar Pharma, Llc Crystallization method and bioavailability
HUE025737T2 (en) 2009-09-01 2016-05-30 Univ Duke Bisphosphonate compositions and methods for treating heart failure
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
JP2014501784A (ja) 2011-01-07 2014-01-23 メリオン・リサーチ・Ｉｉｉ・リミテッド 経口投与用の鉄の医薬組成物
US9949992B2 (en) 2011-11-16 2018-04-24 Duke University Bisphosphonate compositions and methods for treating and\or reducing cardiac dysfunction
CN103623465B (zh) * 2013-11-21 2015-12-30 彭江 一种可局部调节成破骨活性的组织工程骨支架及制备方法
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
KR20180115979A (ko) * 2017-04-14 2018-10-24 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물
GB201716716D0 (en) 2017-10-12 2017-11-29 Univ Of Hertfordshire Higher Education Corporation Method for coating particles
KR20210124958A (ko) * 2018-11-02 2021-10-15 앰퍼샌드 바이오파마슈티컬스, 인코포레이티드 국소적으로 적용되는 완충제(buffers)를 사용하는 양이온 과부하 및 전해질 불균형의 위험 가능성 관리를 위한 제형 및 방법
KR102049233B1 (ko) * 2019-01-14 2019-11-28 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US594329A (en) * 1897-11-23 Socket or collet
DE3232959A1 (de) 1982-09-04 1984-03-08 Hoechst Ag, 6230 Frankfurt Substituierte benzolsulfonsaeureester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE114473T1 (de) 1984-04-30 1994-12-15 Procter & Gamble Ausrüstung für die verwendung bei der behandlung von osteoporose.
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
US4822609A (en) * 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3776880D1 (de) * 1986-11-21 1992-04-02 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
NZ246456A (en) * 1991-12-17 1997-03-24 Procter & Gamble Pharma Use of bone active phosphonate and a parathyroid hormone to prepare medicaments for a thirty day treatment regimen for osteoporosis
EP0648120B1 (en) 1992-06-30 1997-12-29 PROCTER & GAMBLE PHARMACEUTICALS, INC. Use of phosphonates for the treatment of osteoporosis
AU670337B2 (en) * 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
EP0600834A1 (en) 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
CN1157566A (zh) 1994-09-09 1997-08-20 普罗克特和甘保尔公司 用于骨质疏松症的膦酸盐类和甲状旁腺激素
EP0779812A4 (en) 1994-09-09 1997-09-10 Procter & Gamble METHOD FOR TREATING OSTEOPOROSIS USING BONE-ACTIVE PHOSPHONATES AND PARATHORMONE
PT854724E (pt) 1995-09-29 2005-08-31 Novartis Ag Metodo de tratar a doenca navicular em cavalos
US5735810A (en) 1996-06-14 1998-04-07 Becton Dickinson And Company Device for the iontophoretic administration of bisphosphonates
US5730715A (en) * 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
KR100391732B1 (ko) 1997-07-22 2003-07-16 한국 엠에스디 주식회사 골 흡수 억제를 위한 조성물
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
FI109088B (fi) * 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
SE9703691D0 (sv) * 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
IT1296495B1 (it) 1997-11-21 1999-06-25 Prodotti Antibiotici Spa Impiego di bisfosfonati nella preparazione di forme farmaceutiche per somministrazione intramuscolare
GB2336311A (en) 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
CA2308532C (en) 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
AU775079B2 (en) 1999-05-21 2004-07-15 Novartis Ag Pharmaceutical compositions and uses
AU2270101A (en) * 1999-12-20 2001-07-03 Merck & Co., Inc. Pharmaceutical kit
GB0012209D0 (en) 2000-05-19 2000-07-12 Novartis Ag Organic compounds
HU228400B1 (en) 2000-06-20 2013-03-28 Novartis Ag The use of bisphosphonates for treatment of osteoporosis

Also Published As

Publication number Publication date
IL153229A (en) 2007-07-24
HU228400B1 (en) 2013-03-28
WO2001097788A2 (en) 2001-12-27
NO20026117L (no) 2002-12-19
JP2003535889A (ja) 2003-12-02
JP2005247873A (ja) 2005-09-15
DK1296689T3 (da) 2005-11-28
CN1620300A (zh) 2005-05-25
CY1113740T1 (el) 2015-08-05
PT1591122E (pt) 2012-12-12
CA2410201C (en) 2010-10-26
HUP0301164A2 (hu) 2003-08-28
SK18082002A3 (sk) 2003-08-05
AU7410901A (en) 2002-01-02
NZ523086A (en) 2007-07-27
WO2001097788A3 (en) 2002-06-27
EP1296689B3 (en) 2013-02-13
EP1296689A2 (en) 2003-04-02
ES2247123T7 (es) 2013-03-01
ATE304856T1 (de) 2005-10-15
PL358224A1 (en) 2004-08-09
CZ301972B6 (cs) 2010-08-18
NO330459B1 (no) 2011-04-18
SK287278B6 (sk) 2010-05-07
CY2013011I2 (el) 2015-08-05
PL203087B1 (pl) 2009-08-31
HUP0301164A3 (en) 2005-11-28
KR20030015283A (ko) 2003-02-20
CY2013011I1 (el) 2015-08-05
CA2410201A1 (en) 2001-12-27
KR100864743B1 (ko) 2008-10-22
NO20026117D0 (no) 2002-12-19
IL153229A0 (en) 2003-07-06
US20030181421A1 (en) 2003-09-25
CZ20024134A3 (cs) 2003-06-18
ES2394211T3 (es) 2013-01-23
HK1072539A1 (en) 2005-09-02
EP1296689B1 (en) 2005-09-21
DE60113537T2 (de) 2006-06-29
ES2247123T3 (es) 2006-03-01
DE60113537T3 (de) 2013-05-29
AU2001274109B2 (en) 2004-12-23
JP5005188B2 (ja) 2012-08-22
CN1272013C (zh) 2006-08-30
US8052987B2 (en) 2011-11-08
DE60113537D1 (de) 2006-02-02
TWI289451B (en) 2007-11-11
JP4722375B2 (ja) 2011-07-13
BR0111806A (pt) 2003-05-20

Similar Documents

Publication Publication Date Title
MXPA02012682A (es) Metodo para administrar bisfosfonatos.
NZ527157A (en) Compositions for delivering bisphosphonates
DK0756484T3 (da) Vådgranuleringsformulering til diphosphonsyrer
DK0637236T3 (da) Farmaceutisk præparat og fremgangsmåde til dets fremstilling
CY1106482T1 (el) Φαρμακευτικη παρεντepικη συνθεση πepιεχοντας ενα διφωσφονικο
WO2001076577A3 (en) Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
EP1178810B8 (en) Use of bisphosphonic acids for treating angiogenesis
EA004544B2 (ru) Способ ингибирования резорбции костей
EA199700183A1 (ru) Способ уменьшения риска невертебральных переломов костей
PL345287A1 (en) Medicaments containing bisphosphonic acids and derivatives thereof which are provided for preventing and treating autoimmune diseases and allergies
ES2152865A1 (es) Utilizacion de bisfosfonatos en la preparacion de composiciones farmaceuticas para uso intramuscular.
TH158917A (th) วิธีการบริหารบีสฟอสฟอเนต

Legal Events

Date Code Title Description
FG Grant or registration